[1] Brent GA. Clinical practice. Graves' disease[J]. N Eng J Med, 2008, 358(24):2594-2605.  doi: 10.1056/NEJMcp0801880
[2]

梁扩寰, 李绍白.肝脏病学[M]. 2版.北京: 人民卫生出版社, 2003: 1-1231.
[3] Biscoveanu M, Hasinski S. Abnormal results of liver function tests in patients with Graves' disease[J]. Endocr Pract, 2000, 6(5):367-369.  doi: 10.4158/EP.6.5.367
[4] 冯正平, 王富华.甲状腺机能亢进症患者肝功能改变及影响因素的初探[J].第三军医大学学报, 2005, 27(3):212-216.  doi: 10.3321/j.issn:1000-5404.2005.03.030
[5]

刘燚, 袁辉, 杜媛媛, 等.甲亢性肝功能损害的临床特点和相关因素分析.医学信息, 2015, 28(14):27.
[6] 张小云, 钟土泉, 黄江兵.病程长短对甲亢性肝损害患者肝功能及预后的影响[J].实用医技杂志, 2004, 11(6A):837-838.
[7] 吴佳玉, 邱焞功, 江南, 等.甲亢性肝损害54例分析[J].四川医学, 1999, 20(6):580-581.
[8] 张晓霞. 503例甲亢性肝损害患者的临床分析[J].标记免疫分析与临床, 2004, 11(3):145-147.  doi: 10.3969/j.issn.1006-1703.2004.03.007
[9] Russo MW, Galanko JA, Shrestha R, et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States[J]. Liver Transpl, 2004, 10(8):1018-1023.  doi: 10.1002/lt.20204
[10] Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children[J]. J Clin Endocrinol Metab, 2010, 95(7):3260-3267.  doi: 10.1210/jc.2009-2546
[11] Wang MT, Lee WJ, Huang TY, et al. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients:a population-based cohort study[J]. Br J Clin Pharmacol, 2014, 78(3):619-629.  doi: 10.1111/bcp.12336
[12] 潘香颖, 李慧贞.甲状腺功能亢进症伴肝功能受损的131I治疗疗效[J].国际放射医学核医学杂志, 2009, 33(3):179-180.  doi: 10.3760/cma.j.issn.1673-4114.2009.03.013
[13] 王洪生, 袁香坤, 张立东. 131I治疗甲亢肝损害的临床观察[J].放射免疫学杂志, 2007, 20(3):249.  doi: 10.3969/j.issn.1008-9810.2007.03.032
[14] Williams KV, Nayak S, Becker D, et al. Fifty years of experience with propylthiouracil-associated hepatotoxicity:what have we learned?[J]. J Clin Endocrinol Metab, 1997, 82(6):1727-1733.
[15] 钟海蓉.甲状腺功能亢进症131碘治疗后受损肝功的变化[J].四川省卫生管理干部学院学报, 2009, 28(2):150, 159.
[16] 张涛, 孙秀华, 张毛荣, 等. 131治疗甲亢性肝损害278例分析[J].川北医学院学报, 2004, 19(3):73-75.  doi: 10.3969/j.issn.1005-3697.2004.03.064
[17]

Jhummon NP, Tohooloo B, Qu S. Iodine-131 induced hepatotoxicity in previously healthy patients with Graves' disease[J/OL]. Thyroid Res, 2013, 6: 4[2015-03-18].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3637811.
[18] 周芳, 张春玲, 马跃华, 等.甲亢合并白细胞减少的临床特征及转归[J].河南医学研究, 2014, 23(2):27-30.
[19] 蒋宁一, 林岩松, 关海霞, 等. 131I治疗格雷夫斯甲亢指南(2013版).中华核医学与分子影像杂志, 2013, 33(2):83- 95.  doi: 10.3760/cma.j.issn.2095-2848.2013.02.002
[20] 郭满涛, 李亚明, 尹雅芙, 等.甲状腺功能亢进伴白细胞减少患者放射性碘治疗早期白细胞变化随访研究[J].重庆医学, 2012, 41(1):28-30.  doi: 10.3969/j.issn.1671-8348.2012.01.010
[21] Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies(ANCA):possible involvement of complement in granulocyte cytotoxicity[J]. Clin Exp Immunol, 2002, 127(1):92-98.  doi: 10.1046/j.1365-2249.2002.01720.x
[22]

陆再英, 钟南山.内科学[M]. 7版.北京: 人民卫生出版社, 2008.
[23] Nakamura H, Miyauchi A, Miyawaki N, et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan[J]. J Clin Endocrinol Metab, 2013, 98(12):4776-4783.  doi: 10.1210/jc.2013-2569
[24] Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage:a retrospective cohort study of agranulocytosis and pancytopenia involving 50, 385 patients with Graves' disease[J]. J Clin Endocrinol Metab, 2012, 97(1):E49-E53.  doi: 10.1210/jc.2011-2221
[25] Tajiri J, Noguchi S. Antithyroid drug-induced agranulocytosis:special reference to normal white blood cell count agranulocytosis. Thyroid, 2004, 14(6):459-462.  doi: 10.1089/105072504323150787
[26] Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily[J]. Thyroid, 2009, 19(6):559-563.  doi: 10.1089/thy.2008.0364
[27] Nakamura H, Noh JY, Itoh K, et al. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease[J]. J Clin Endocrinol Metabo, 2007, 92(6):2157-2162.  doi: 10.1210/jc.2006-2135
[28] 蒋宁一, 匡安仁, 谭建, 等. 131I治疗Graves甲亢专家共识(2010年)[J].中华核医学杂志, 2010, 30(5):346-351.  doi: 10.3760/cma.j.issn.0253-9780.2010.05.019
[29] 李小平, 何云南, 胡庆武. 131I治疗甲亢患者疗效观察及其对外周血液的影响[J].放射免疫学杂志, 2004, 17(6):473-476.  doi: 10.3969/j.issn.1008-9810.2004.06.041
[30]

谭天秩.临床核医学[M]. 2版.北京: 人民卫生出版社, 2003: 1218-1250.
[31] 黄际远, 宋文忠, 戴庆靖, 等. Graves甲亢伴白细胞减少患者131I治疗[J].临床血液学杂志, 2012, 25(1):42-43.
[32] 石丽红, 蒋宁一, 孙云凤, 等.格雷夫斯甲亢合并白细胞减少患者131I治疗临床分析[J].中华核医学与分子影像杂志, 2013, 33(2):120-123.  doi: 10.3760/cma.j.issn.2095-2848.2013.02.005
[33] 张王峰, 叶常青, 袁梦晖, 等. 131碘内照射治疗对甲状腺功能亢进患者白细胞的影响[J].华北国防医药, 2010, 22(3):208-210.  doi: 10.3969/j.issn.2095-140X.2010.03.003
[34] 许泽清, 邓俊, 唐彩华. 131I治疗ATD治疗后白细胞减少Graves病近期疗效观察[J].中国实用医药, 2012, (10):109-110.  doi: 10.3969/j.issn.1673-7555.2012.10.072
[35] 文晓琴, 欧阳良, 胡健康, 等.碳酸锂联合131I治疗Graves病合并白细胞减少症的效果分析[J].天津医药, 2014, 42(8):782-785.  doi: 10.3969/j.issn.0253-9896.2014.08.013
[36] 许泽清, 贾晓娟, 唐彩华.碳酸锂联合131I治疗合并白细胞减少的严重Graves病近期疗效观察[J].实用医技杂志, 2012, 19(7):689-690.  doi: 10.3969/j.issn.1671-5098.2012.07.007
[37] 迟志波, 孙宝莹, 闫萍.泼尼松治疗Graves病甲亢合并白细胞减少疗效观察[J].山东医药, 2005, 45(34):28.  doi: 10.3969/j.issn.1002-266X.2005.34.033